Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 5798734, 8 pages
https://doi.org/10.1155/2017/5798734
Research Article

Antidyskinetic Treatment with MTEP Affects Multiple Molecular Pathways in the Parkinsonian Striatum

Department of Neurology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China

Correspondence should be addressed to Zhen-guo Liu; moc.nuyila@4002uilougnehz

Received 17 February 2017; Revised 8 May 2017; Accepted 17 September 2017; Published 30 October 2017

Academic Editor: Francisco Grandas

Copyright © 2017 Jing-ya Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Feyder, A. Bonito-Oliva, and G. Fisone, “L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: Focus on dopamine D1 receptor-mediated transmission,” Frontiers in Behavioral Neuroscience, no. OCTOBER, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Calabresi, M. D. Filippo, V. Ghiglieri, N. Tambasco, and B. Picconi, “Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap,” The Lancet Neurology, vol. 9, no. 11, pp. 1106–1117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Niccolini, L. Rocchi, and M. Politis, “Molecular imaging of levodopa-induced dyskinesias,” Cellular and Molecular Life Sciences, vol. 72, no. 11, pp. 2107–2117, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Winkler, D. Kirik, A. Björklund, and M. A. Cenci, “L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: Relation to motor and cellular parameters of nigrostriatal function,” Neurobiology of Disease, vol. 10, no. 2, pp. 165–186, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Marin, M. Bonastre, G. Mengod, R. Cortés, and M. C. Rodríguez-Oroz, “From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms,” Neuropharmacology, vol. 97, pp. 365–375, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Cenci, C. S. Lee, and A. Björklund, “L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA,” European Journal of Neuroscience, vol. 10, no. 8, pp. 2694–2706, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Cenci, “Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia,” Trends in Neurosciences, vol. 30, no. 5, pp. 236–243, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Sgroi, C. Capper-Loup, P. Paganetti, and A. Kaelin-Lang, “Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats,” Experimental Neurology, vol. 280, pp. 80–88, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Rylander, A. Recchia, F. Mela, A. Dekundy, W. Danysz, and M. A. Cenci Nilsson, “Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: Effects on motor behavior and striatal nuclear signaling,” The Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 1, pp. 227–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. X.-B. Cao, Q. Guan, Y. Xu, L. Wang, and S.-G. Sun, “Mechanism of over-activation in direct pathway mediated by dopamine D1 receptor in rats with levodopa-induced dyskinesias,” Neuroscience Bulletin, vol. 22, no. 3, pp. 159–164, 2006. View at Google Scholar · View at Scopus
  11. K. A. Johnson, P. J. Conn, and C. M. Niswender, “Glutamate receptors as therapeutic targets for Parkinson's disease,” CNS & Neurological Disorders—Drug Targets, vol. 8, no. 6, pp. 475–491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Tison, C. Keywood, M. Wakefield et al., “A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease,” Movement Disorders, vol. 31, no. 9, pp. 1373–1380, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. A. R. Salomons, N. E. Pinzon, H. Boleij et al., “Differential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice,” Behavioral and Brain Functions, vol. 8, article 30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Rascol, S. Perez-Lloret, and J. J. Ferreira, “New treatments for levodopa-induced motor complications,” Movement Disorders, vol. 30, no. 11, pp. 1451–1460, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Mela, M. Marti, A. Dekundy, W. Danysz, M. Morari, and M. A. Cenci, “Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease,” Journal of Neurochemistry, vol. 101, no. 2, pp. 483–497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Dekundy, M. Pietraszek, D. Schaefer, M. A. Cenci, and W. Danysz, “Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease,” Brain Research Bulletin, vol. 69, no. 3, pp. 318–326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Sgambato-Faure and M. A. Cenci, “Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease,” Progress in Neurobiology, vol. 96, no. 1, pp. 69–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Nicoletti, J. Bockaert, G. L. Collingridge et al., “Metabotropic glutamate receptors: from the workbench to the bedside,” Neuropharmacology, vol. 60, no. 7-8, pp. 1017–1041, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Song, Z. Zhang, R. Hu et al., “Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats,” Drug Design, Development and Therapy, vol. 10, pp. 547–555, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-L. Xie, J.-Y. Lin, M.-H. Wang et al., “Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats,” Scientific Reports, vol. 6, Article ID 23527, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Rylander, H. Iderberg, Q. Li et al., “A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys,” Neurobiology of Disease, vol. 39, no. 3, pp. 352–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. P. S. Smith, J. D. Oh, F. Bibbiani, M. A. Collins, I. Avila, and T. N. Chase, “Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates,” Neuropharmacology, vol. 52, no. 2, pp. 515–526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. E. Westin, L. Vercammen, E. M. Strome, C. Konradi, and M. A. Cenci, “Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors,” Biological Psychiatry, vol. 62, no. 7, pp. 800–810, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Awad, G. W. Hubert, Y. Smith, A. I. Levey, and P. J. Conn, “Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus,” The Journal of Neuroscience, vol. 20, no. 21, pp. 7871–7879, 2000. View at Google Scholar · View at Scopus
  25. S. Zhang, C. Xie, Q. Wang, and Z. Liu, “Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats,” Scientific Reports, vol. 4, article 6811, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. H. S. Lindgren, D. R. Andersson, S. Lagerkvist, H. Nissbrandt, and M. A. Cenci, “L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: Temporal and quantitative relationship to the expression of dyskinesia,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1465–1476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Yang, H. Zhao, H. Shi et al., “Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease,” Experimental Neurology, vol. 271, pp. 168–174, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Santini, E. Valjent, and G. Fisone, “Parkinson's disease: levodopa-induced dyskinesia and signal transduction,” FEBS Journal, vol. 275, no. 7, pp. 1392–1399, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Pavón, A. B. Martín, A. Mendialdua, and R. Moratalla, “ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice,” Biological Psychiatry, vol. 59, no. 1, pp. 64–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Fieblinger, I. Sebastianutto, C. Alcacer et al., “Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5,” The Journal of Neuroscience, vol. 34, no. 13, pp. 4728–4740, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Yamamoto and J.-J. Soghomonian, “Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by L-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats,” Neuroscience, vol. 163, no. 4, pp. 1171–1180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Henry, S. Duty, S. H. Fox, A. R. Crossman, and J. M. Brotchie, “Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease,” Experimental Neurology, vol. 183, no. 2, pp. 458–468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Beaulieu, T. D. Sotnikova, S. Marion, R. J. Lefkowitz, R. R. Gainetdinov, and M. G. Caron, “An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior,” Cell, vol. 122, no. 2, pp. 261–273, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Morissette, P. Samadi, A. H. Tahar, N. Bélanger, and T. Di Paolo, “Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 34, no. 3, pp. 446–454, 2010. View at Publisher · View at Google Scholar · View at Scopus